

# Coromandel International

Estimate change	↔
TP change	↑
Rating change	↔

Bloomberg	CRIN IN
Equity Shares (m)	295
M.Cap.(INRb)/(USDb)	720.2 / 8.3
52-Week Range (INR)	2647 / 1544
1, 6, 12 Rel. Per (%)	6/28/50
12M Avg Val (INR M)	1257

## Financials & Valuations (INR b)

Y/E Mar	2025	2026E	2027E
Sales	240.9	297.1	324.9
EBITDA	26.3	32.6	39.8
PAT	18.0	22.4	28.7
EBITDA (%)	10.9	11.0	12.3
EPS (INR)	61.3	76.2	97.4
EPS Gr. (%)	9.8	24.4	27.8
BV/Sh. (INR)	376.6	438.8	522.2
<b>Ratios</b>			
Net D/E	-0.3	-0.2	-0.4
RoE (%)	17.6	18.7	20.3
RoCE (%)	19.7	19.8	20.9
Payout (%)	19.9	18.4	14.4
<b>Valuations</b>			
P/E (x)	39.8	32.0	25.1
EV/EBITDA (x)	26.1	21.1	16.6
Div Yield (%)	0.6	0.6	0.6
FCF Yield (%)	2.8	-0.1	4.1

## Shareholding pattern (%)

As On	Jun-25	Mar-25	Jun-24
Promoter	56.9	57.0	57.3
DII	15.9	19.0	20.8
FII	14.4	10.6	7.5
Others	12.9	13.5	14.4

**CMP: INR2,443**

**TP: INR2,930 (+20%)**

**Buy**

## Strong 1QFY26 lays solid foundation for FY26

### Operating performance in line with estimates

- Coromandel International (CRIN) continued to deliver strong operating performance in 1QFY26 (EBIT up 50% YoY), supported by continued traction in crop protection (EBIT up 77% YoY) and nutrients and allied (EBIT up 46% YoY). Margin expansion was driven by higher manufactured volumes (up 12% YoY), procurement efficiencies, operating leverage, and effective marketing initiatives.
- We expect this momentum to sustain, driven by a favorable agricultural scenario with above-normal monsoon. Moreover, rising demand for crop protection, along with easing global agrochemical channel inventories, is expected to support segment growth. Management's focus on capacity expansion and the introduction of new molecules in the crop protection segment is expected to reinforce growth going forward.
- We largely maintain our FY26 earnings estimates but raise our FY27 estimates by 6%, driven by enhanced backward integration through an increase in phosphoric acid capacity in FY27. We value the company at ~30x FY27E EPS to arrive at a **TP of INR2,930. Reiterate BUY**

### Strong performance across each segment drives profitability

- CRIN reported total revenue of INR70.4b (est. INR62b) in 1QFY26, up 49% YoY, led by higher sales volume. Total manufacturing fertilizer volumes (NPK+DAP) grew 10% YoY to ~0.9mmt and total phosphate fertilizer manufacturing volumes (including SSP) rose 12% YoY to 1.08mmt.
- Nutrient & other allied business revenue rose 51% YoY to INR63.5b, while crop protection business revenue grew 31% YoY to INR7.2b.
- EBITDA surged 55% YoY to INR7.8b (est. in-line). According to our calculations, manufacturing EBITDA/mt (including SSP) stood at INR5,118 (up 20% YoY), while EBITDA/mt for phosphate fertilizers (DAP and NPK) stood at INR5,937 (up 23% YoY).
- EBIT margin for the nutrient & other allied business contracted 30bp YoY to 9.9%, while EBIT margin for the crop protection business expanded ~400bp YoY to 15.3%.
- Adjusted PAT stood at INR5b (est. in line), up 62% YoY.

### Highlights from the management commentary

- Baobab Mining and Chemicals Corporation SA, Senegal (BMCC):** The Board of Directors approved the acquisition of an additional 17.69% stake, increasing overall shareholding in BMCC to 71.51% through its wholly-owned subsidiary. This strategic move is aimed at further strengthening backward integration in the phosphates value chain. BMCC, based in Senegal, is primarily engaged in the mining and production of rock phosphate
- Subsidy:** During the quarter, CRIN received INR13b in subsidy claims, compared to INR9.87b in 1QFY25. As of Jun'25, outstanding subsidies stood at ~INR29.1b compared to INR19.7b as of Jun'24.

**Research Analyst: Sumant Kumar** (Sumant.Kumar@MotilalOswal.com) | **Meet Jain** (Meet.Jain@MotilalOswal.com)

**Research Analyst: Nirvik Saini** (Nirvik.Saini@MotilalOswal.com) | **Yash Darak** (Yash.Darak@ MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

- **Capacity expansion:** Backward integration projects for the phosphoric and sulphuric acid plants at Kakinada are progressing well, with commissioning expected by 4QFY26. Additionally, the company has initiated preliminary work on a 750,000-ton fertilizer granulation facility at Kakinada, targeted to commence operations by CY28.

### Valuation and view

- We believe the company is well-positioned to sustain its growth momentum in FY26, supported by favorable market dynamics, a continued decline in global agrochemical channel inventory, and an increasing shift toward NPK fertilizers.
- CRIN's longer-term outlook is further backed by: 1) continuous backward integration for the fertilizer business; 2) product innovation and diversification; 3) differentiated and unique grades; and 4) expansion into new geographies.
- We largely maintain our FY26 earnings estimates but raise our FY27 estimates by 6%. We expect a CAGR of ~16%/23%/26% in revenue/EBITDA/adj. PAT over FY25-27. We value CRIN at ~30x FY27E EPS to arrive at our TP of INR2,930. **Reiterate BUY.**

### Quarterly Performance


Y/E March	(INR m)											
	FY25				FY26E				FY25	FY26E	FY26	Var
Consolidated	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1E	%
Net Sales	47,288	74,328	69,352	49,884	70,423	86,090	82,083	58,478	240,852	297,074	61,910	14
YoY Change (%)	-16.9	6.4	26.9	27.5	48.9	15.8	18.4	17.2	9.2	23.3	30.9	
Total Expenditure	42,231	64,581	62,134	45,624	62,602	74,784	73,851	53,228	214,569	264,465	54,270	
EBITDA	5,058	9,748	7,218	4,260	7,821	11,306	8,233	5,249	26,283	32,609	7,641	2
Margins (%)	10.7	13.1	10.4	8.5	11.1	13.1	10.0	9.0	10.9	11.0	12.3	
Depreciation	653	690	708	854	1,206	1,100	1,210	1,220	2,904	4,736	760	
Interest	574	661	731	659	680	660	550	450	2,624	2,340	600	
Other Income	541	650	1,137	1,260	837	900	1,307	1,389	3,587	4,433	649	
PBT before EO expense	4,372	9,047	6,916	4,007	6,773	10,446	7,780	4,968	24,342	29,967	6,930	
Extra-Ord expense	0	0	0	-3,468	0	0	0	0	-3,468	0	0	
PBT	4,372	9,047	6,916	7,475	6,773	10,446	7,780	4,968	27,810	29,967	6,930	
Tax	1,125	2,328	1,752	1,524	1,757	2,629	1,958	1,250	6,728	7,595	1,744	
Rate (%)	25.7	25.7	25.3	20.4	25.9	25.2	25.2	25.2	24.2	25.3	25.2	
Minority Interest & P/L of Asso. Cos.	137	79	46	154	-34	-50	-80	100	417	-64	144	
Reported PAT	3,110	6,641	5,118	5,797	5,050	7,867	5,902	3,618	20,665	22,436	5,042	
Adj PAT	3,110	6,641	5,118	3,036	5,050	7,867	5,902	3,618	18,036	22,436	5,042	0
YoY Change (%)	-37.1	-12.3	121.6	89.4	62.4	18.5	15.3	19.2	9.8	24.4	62.1	
Margins (%)	6.6	8.9	7.4	6.1	7.2	9.1	7.2	6.2	7.5	7.6	8.1	

### Key Performance Indicators


Y/E March	FY25				FY26		FY25	FY26E
	1Q	2Q	3Q	4Q	1Q			
Consolidated								
Volume Growth (%)	-3.4	24.6	14.6	23.6	28.2	14.9	11.6	
Manufacturing (%)	3.3	6.3	7.6	22.8	11.8	8.7	9.0	
Trading (%)	-22.4	116.1	28.3	24.8	89.9	30.6	89.9	
Mfg EBITDA/MT (INR)	4,261	5,435	4,609	4,177	5,118	4,150	4,605	
Cost Break-up								
RM Cost (% of sales)	73.6	74.9	76.4	70.3	74.4	74.1	73.9	
Staff Cost (% of sales)	3.9	2.5	3.0	4.2	3.2	3.3	3.1	
Freight Cost (% of sales)	6.0	5.0	5.4	6.4	5.4	5.6	5.4	
Other Cost (% of sales)	5.8	4.5	4.9	10.6	5.9	6.1	6.5	
Gross Margins (%)	26.4	25.1	23.6	29.7	25.6	25.9	26.1	
EBITDA Margins (%)	10.7	13.1	10.4	8.5	11.1	10.9	11.0	
EBIT Margins (%)	9.3	12.2	9.4	6.8	9.4	9.7	9.4	

## Key exhibits


### Exhibit 1: Revenue trend




### Exhibit 2: EBITDA trend




### Exhibit 3: Adjusted PAT trend



### Exhibit 4: Trend in outstanding subsidy



### Exhibit 5: Price trend in phosphoric acid



**Exhibit 6: Segmental revenue and EBIT trends**

INR m	1QFY25	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
<b>Segment revenue</b>									
Nutrient and Other Allied	52,006	63,017	49,027	33,702	42,137	67,503	63,674	43,210	63,517
YoY growth (%)	2%	-33%	-36%	-31%	-19%	7%	30%	28%	51%
Crop Protection	5,475	7,301	6,154	5,644	5,516	7,511	6,357	6,987	7,249
YoY growth (%)	-17%	3%	-6%	-8%	1%	3%	3%	24%	31%
Less: Inter-segment	547	437	540	219	364	686	678	313	343
<b>Total</b>	<b>56,934</b>	<b>69,881</b>	<b>54,642</b>	<b>39,127</b>	<b>47,288</b>	<b>74,328</b>	<b>69,352</b>	<b>49,884</b>	<b>70,423</b>
<b>Segment EBIT</b>									
Nutrient and Other Allied	6,717	9,913	2,516	2,515	4,317	8,507	6,261	2,973	6,295
Margin (%)	12.9%	15.7%	5.1%	7.5%	10.2%	12.6%	9.8%	6.9%	9.9%
Crop Protection	550	871	846	631	629	1,083	910	1,011	1,112
Margin (%)	10.0%	11.9%	13.7%	11.2%	11.4%	14.4%	14.3%	14.5%	15.3%
Unallocated expenses	656	737	419	1,046	540	532	661	1,088	-791
<b>Total</b>	<b>6,611</b>	<b>10,048</b>	<b>2,943</b>	<b>2,100</b>	<b>4,405</b>	<b>9,058</b>	<b>6,510</b>	<b>2,897</b>	<b>8,197</b>

Source: Company, MOFSL

**Exhibit 7: Volume trend**

Quarterly volume trend ('000MT)	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
<b>Manufactured</b>									
NPK	714	994	817	506	726	1,086	912	607	893
Growth (%)	14%	-7%	-8%	-5%	2%	9%	12%	20%	23%
DAP	44	33	59	33	85	0	0	0	0
Growth (%)	-25%	-3%	111%	371%	93%	-100%	-100%	-100%	-100%
SSP	179	212	143	119	157	231	184	201	189
Growth (%)	13%	-13%	-34%	-37%	-12%	9%	29%	69%	20%
<b>Total Manufacturing</b>	<b>937</b>	<b>1,239</b>	<b>1,019</b>	<b>658</b>	<b>968</b>	<b>1,317</b>	<b>1,096</b>	<b>808</b>	<b>1,082</b>
Growth (%)	11%	-8%	-10%	-10%	3%	6%	8%	23%	12%
<b>Traded</b>									
MOP	11	37	22	12	7	29	20	13	6
Growth (%)	175%	85%	1000%	1100%	-36%	-22%	-9%	8%	-14%
DAP Traded	97	132	62	51	27	181	227	97	193
Growth (%)	149%	-4%	-54%	-41%	-72%	37%	266%	90%	615%
NPK Traded	0	0	0	0	0	43	0	0	14
Urea	223	79	436	372	223	283	420	433	275
Growth (%)	36%	-79%	9%	-31%	0%	258%	-4%	16%	23%
<b>Total Trading</b>	<b>331</b>	<b>248</b>	<b>520</b>	<b>435</b>	<b>257</b>	<b>536</b>	<b>667</b>	<b>543</b>	<b>488</b>
Growth (%)	60%	-53%	-3%	-31%	-22%	116%	28%	25%	90%
<b>Total Trading + Mfg.</b>	<b>1,268</b>	<b>1,487</b>	<b>1,539</b>	<b>1,093</b>	<b>1,225</b>	<b>1,853</b>	<b>1,763</b>	<b>1,351</b>	<b>1,570</b>
Growth (%)	20%	-21%	-8%	-20%	-3%	25%	15%	24%	28%
<b>Total NPK (mfg. + trading)</b>	<b>714</b>	<b>994</b>	<b>817</b>	<b>506</b>	<b>726</b>	<b>1,129</b>	<b>912</b>	<b>607</b>	<b>907</b>
Growth (%)	14%	-7%	-8%	-5%	2%	14%	12%	20%	25%
<b>Total DAP (mfg. + trading)</b>	<b>141</b>	<b>165</b>	<b>121</b>	<b>84</b>	<b>112</b>	<b>181</b>	<b>227</b>	<b>97</b>	<b>193</b>
Growth (%)	44%	-4%	-26%	-11%	-21%	10%	88%	15%	72%
<b>Total phosphatic fertilizer</b>	<b>855</b>	<b>1,159</b>	<b>938</b>	<b>590</b>	<b>838</b>	<b>1,310</b>	<b>1,139</b>	<b>704</b>	<b>1,100</b>
Growth (%)	18%	-7%	-11%	-6%	-2%	13%	21%	19%	31%

Source: Company, MOFSL



## Highlights from the management commentary

### Industry scenario

- After an early onset of the southwest monsoon in May, the country witnessed above-normal rains during the first half of the kharif season.
- While regional variation exists, there has been good recovery, especially over the last fortnight, and overall agriculture scenario remains positive.
- Reservoir capacities have increased to 61% from 38% last year.
- Overall, crop sowing has reached 70m hectares against the total kharif target of 109 million hectares, indicating that around 70% of the sowing has been completed.
- The government has extended strong support to farm incomes by raising minimum support prices for Kharif 2025 crops.
- Overall, primary sales at the industry level grew 9%, driven mainly by NPK, which rose 34% from 220k tons to 290k tons, while DAP witnessed a decline. This indicates farmers' preference for balanced nutrition and choices influenced by product availability.
- DAP prices continue to remain lower compared to the higher pricing of NPK.
- Potash consumption in primary sales increased; however, imports declined significantly due to delays in price negotiation.

### Operating performance

- CRIN made a strong start to the season, delivering growth across businesses, driven by procurement efficiencies, operational excellence, and effective marketing initiatives.
- Higher subsidiary rates and volume growth across all business segments were the key drivers of revenue.
- Performance was further aided by an early monsoon onset, which led to higher crop sowing and increased agri-input consumption.
- In 1QFY26, plants operated at full capacity of 840k tons, registering 6% volume growth.
- CRIN continues to operate the newly commissioned sulphuric acid plant at 100% capacity utilization.
- The share of unique grades, which differentiates CRIN from the rest of the players, stands at 34%, marking an improvement from last year's 31%.
- CRIN continues to expand in Central and Northern India, aligning with its strategy to diversify markets.
- The formulation business recorded 33% volume growth, with exports growing nearly 20%, while biological volumes have doubled.

### Subsidy

- The subsidy/non-subsidy business share stood at ~83%/17% in 1QFY26, compared to ~81%/19% in 1QFY25.
- During 1QFY26, the company received INR13b toward subsidy claims, compared INR9.87b in 1QFY25.
- As of Jun'25, outstanding subsidy stands at ~INR29.1b, compared to INR19.7b in Jun'24.

### DAP

- A government delegation recently visited Saudi Arabia and secured a long-term supply agreement of ~3.1mt for the coming years. This is significant, as India imports 5mt-6mt of DAP.
- Considering the importance of DAP requirement, the government has also come up with additional compensation for DAP beyond a certain threshold level.
- Phosphate prices like DAP continued to rise as the continued absence of Chinese exports and reduced supply from Russia have significantly tightened global market availability.
- There has been a shortfall in DAP supplies from China, leading to increased DAP prices.
- The nano DAP business has made good progress and management has been highly systematic in creating awareness campaigns across India.
- China has been a major source of supply for India in recent years; however, imports from China have completely dried up in the current year, leading to a demand-supply mismatch.
- The company remains confident that increased volumes from the Middle East can compensate for the shortfall from China, which should help ease the overall supply situation significantly.
- Domestically, companies are also adding capacities that are expected to come on stream over the next two years, which should further help alleviate supply constraints in the medium term.

### NPK

- The NPK segment continued to grow well, accounting for 65% of overall sales.
- The company is looking to diversify its portfolio by exploring Nano NPKs.

### Crop protection business

- Globally, in agrochemicals, there has been a reduction in channel inventory compared to last year.
- Pricing pressure on certain molecules has improved compared to last year but still persists.
- Favorable monsoon conditions in the domestic market have supported widespread spraying coverage across the region, generating demand for crop protection.
- The company's phosphatic fertilizer business recorded 31% volume growth, driven by its improving presence in existing markets and penetration into new markets.
- Plants operated close to full capacity with enhanced production of intermediates.
- The rock phosphate project at Senegal has stabilized and is delivering consistent rock supplies to phosphoric acid plants in India.
- The crop protection segment's sales and margins grew during the quarter, driven by strong performance in both domestic and international markets.
- CRIN introduced 10 new products, including an in-licensing molecule and three 9(3) formulations, further strengthening its portfolio offerings.
- The company witnessed strong demand for bio products in global markets, especially from the US, with consistent orders from Europe as well.

- The consumption of fertilizers has increased 9% to 4.5mt yearly. The arrival of monsoon, lower level of inventory, and higher sowings contributed to the improved consumption trend.

### Retail

- The retail business continued its expansion, adding 73 stores during the quarter. It is on track to increase its footprint to 1,200 stores by the end of the year, adding another 400 stores.
- The retail business is enhancing its customer outreach through strengthened e-commerce and digital platforms.
- CRIN will be the only player to make a door delivery of key agri-input products besides providing spraying services.

### BMCC

- The Board of Directors approved the acquisition of an additional 17.69% issued share capital of BMCC through its wholly-owned subsidiary for a consideration of USD7.7m, bringing the overall shareholding in BMCC to 71.51%.
- The acquisition of an additional stake in BMCC is a strategic move to further strengthen its backward integration in the phosphates value chain.
- The company's rock phosphate project at BMCC has stabilized its operation, enabling the company to efficiently meet the stock requirements.

### Others

- The Specialty & Organic, Bio, Nano Fertilizers, and Gromor Drive businesses delivered robust performance, strengthening the company's integrated crop management approach.
- Backward integration projects for phosphoric and sulphuric acid plants at Kakinada are progressing well and likely to be commissioned by 4QFY26.
- CRIN has also initiated groundwork for setting up a 750k ton fertilizer granulation facility at Kakinada and is on track to open it by CY28.
- The company has signed a long-term agreement with Maaden, a leading fertilizer player based in Kingdom of Saudi Arabia, for securing DAP shipments to India.
- CRIN has set up a joint venture with Sakarni Plaster to manufacture and market PhoSum-based green building materials by utilizing its industrial by-products.
- Going forward, the company aims to broaden its portfolio from institutional partnerships and tap into export markets to enhance its presence.
- Management has also started focusing intensely on the domestic formulation segments and expanding into different geographies by significantly improving the company's presence in additional 40 territories.
- The company has received approval from the Competition Commission for the newly acquired NACL and is awaiting clearance from SEBI to launch the open offer.
- Phosphoric acid prices increased USD1153/MT in 1QFY26 and are expected to reach USD1258/MT in 2QFY26.
- Sulfur and sulfuric acid prices have remained firm, with sulfuric acid currently priced at around USD120 per ton. Sulfur prices had peaked at USD300 but have recently softened.

### Valuation and view

- We believe the company is well-positioned to sustain its growth momentum in FY26, supported by favorable market dynamics, a continued decline in global agrochemical channel inventory, and an increasing shift toward NPK fertilizers.
- CRIN's longer-term outlook is further backed by: 1) continuous backward integration for the fertilizer business; 2) product innovation and diversification; 3) differentiated and unique grades; and 4) expansion into new geographies.
- We largely maintain our FY26 earnings estimates but raise our FY27 estimates by 6%. We expect a CAGR of ~16%/23%/26% in revenue/EBITDA/adj. PAT over FY25-27E. We value CRIN at ~30x FY27E EPS to arrive at our TP of INR2,930. **Reiterate BUY.**

### Exhibit 8: Revisions to our estimates

Earnings Change (INR m)	Old		New		Change	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	288,219	314,952	297,074	324,880	3%	3%
EBITDA	32,435	36,786	32,609	39,815	1%	8%
Adj. PAT	22,971	26,951	22,436	28,672	-2%	6%

Source: MOFSL

## Financials and valuations

Consolidated - Income Statement								(INRm)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Income from Operations	131,367	141,820	191,109	296,279	220,584	240,852	297,074	324,880
Less: Excise Duty	0	0	0	0	0	0	0	0
<b>Total Income from Operations</b>	<b>131,367</b>	<b>141,820</b>	<b>191,109</b>	<b>296,279</b>	<b>220,584</b>	<b>240,852</b>	<b>297,074</b>	<b>324,880</b>
Change (%)	(0.7)	8.0	34.8	55.0	(25.5)	9.2	23.3	9.4
<b>Total Expenditure</b>	<b>114,057</b>	<b>121,977</b>	<b>169,610</b>	<b>267,017</b>	<b>196,596</b>	<b>214,569</b>	<b>264,465</b>	<b>285,065</b>
<b>EBITDA</b>	<b>17,310</b>	<b>19,843</b>	<b>21,499</b>	<b>29,262</b>	<b>23,988</b>	<b>26,283</b>	<b>32,609</b>	<b>39,815</b>
Margin (%)	13.2	14.0	11.2	9.9	10.9	10.9	11.0	12.3
Depreciation	1,580	1,731	1,727	1,820	2,286	2,904	4,736	5,309
<b>EBIT</b>	<b>15,730</b>	<b>18,112</b>	<b>19,772</b>	<b>27,442</b>	<b>21,702</b>	<b>23,379</b>	<b>27,873</b>	<b>34,506</b>
Int. and Finance Charges	2,353	1,057	755	1,900	1,866	2,624	2,340	1,600
Other Income	400	751	1,443	1,711	2,314	3,587	4,433	5,320
<b>PBT bef. EO Exp.</b>	<b>13,777</b>	<b>17,806</b>	<b>20,460</b>	<b>27,253</b>	<b>22,150</b>	<b>24,342</b>	<b>29,967</b>	<b>38,226</b>
EO Expense/(Income)	0	0	0	0	0	3,468	0	0
<b>PBT after EO Exp.</b>	<b>13,777</b>	<b>17,806</b>	<b>20,460</b>	<b>27,253</b>	<b>22,150</b>	<b>27,810</b>	<b>29,967</b>	<b>38,226</b>
Total Tax	3,135	4,568	5,213	6,879	5,478	6,728	7,595	9,622
Tax Rate (%)	22.8	25.7	25.5	25.2	24.7	24.2	25.3	25.2
Less: MI/Sh of profit/loss of JV & Ass.	-8	-54	-37	245	250	417	-64	-67
<b>Reported PAT</b>	<b>10,650</b>	<b>13,292</b>	<b>15,285</b>	<b>20,129</b>	<b>16,422</b>	<b>20,665</b>	<b>22,436</b>	<b>28,672</b>
<b>Adjusted PAT</b>	<b>10,650</b>	<b>13,292</b>	<b>15,285</b>	<b>20,129</b>	<b>16,422</b>	<b>18,036</b>	<b>22,436</b>	<b>28,672</b>
Change (%)	43.1	24.8	15.0	31.7	-18.4	9.8	24.4	27.8
Margin (%)	8.1	9.4	8.0	6.8	7.4	7.5	7.6	8.8

Consolidated - Balance Sheet								(INRm)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	293	293	294	294	294	294	294	294
Total Reserves	42,884	51,213	63,289	78,784	93,905	110,584	128,898	153,448
<b>Net Worth</b>	<b>43,177</b>	<b>51,506</b>	<b>63,583</b>	<b>79,078</b>	<b>94,199</b>	<b>110,878</b>	<b>129,193</b>	<b>153,743</b>
Deferred Liabilities	578	576	660	591	827	837	837	837
Total Loans	16,251	16	0	46	518	2,322	1,322	822
<b>Capital Employed</b>	<b>60,007</b>	<b>52,098</b>	<b>64,243</b>	<b>79,715</b>	<b>95,814</b>	<b>115,386</b>	<b>132,701</b>	<b>156,751</b>
Gross Block	31,166	36,849	39,337	42,245	46,769	51,506	66,031	75,531
Less: Accum. Deprn.	14,967	16,698	18,424	20,244	22,529	25,433	30,169	35,477
<b>Net Fixed Assets</b>	<b>16,200</b>	<b>20,151</b>	<b>20,913</b>	<b>22,001</b>	<b>24,240</b>	<b>26,073</b>	<b>35,862</b>	<b>40,053</b>
Goodwill on Consolidation	3	3	3	3	2,849	2,849	2,849	2,849
Capital WIP	654	898	1,412	3,993	2,355	3,525	7,000	2,500
Current Investments	0	0	0	0	0	0	0	0
<b>Total Investments</b>	<b>2,113</b>	<b>2,138</b>	<b>2,435</b>	<b>2,867</b>	<b>8,538</b>	<b>10,308</b>	<b>10,308</b>	<b>10,308</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>82,517</b>	<b>65,765</b>	<b>88,085</b>	<b>113,484</b>	<b>120,534</b>	<b>146,418</b>	<b>155,182</b>	<b>186,769</b>
Inventory	26,971	26,009	36,632	44,165	46,125	47,699	52,904	57,855
Account Receivables	17,341	5,544	2,649	5,893	13,935	12,291	13,836	14,241
Govt Subsidies Receivable	23,162	5,897	2,941	23,779	13,772	16,536	20,348	22,252
Cash and Bank Balance	783	7,221	17,533	14,178	28,586	35,383	31,469	60,378
Loans and Advances	14,259	21,094	28,330	25,470	18,116	34,509	36,626	32,043
<b>Curr. Liability &amp; Prov.</b>	<b>41,481</b>	<b>36,857</b>	<b>48,605</b>	<b>62,633</b>	<b>62,702</b>	<b>73,890</b>	<b>78,603</b>	<b>85,832</b>
Account Payables	33,481	29,222	39,135	53,138	53,606	60,300	66,190	71,419
Other Current Liabilities	7,643	7,281	9,132	9,057	8,606	12,995	11,395	13,351
Provisions	357	354	337	439	489	595	1,019	1,061
<b>Net Current Assets</b>	<b>41,036</b>	<b>28,908</b>	<b>39,481</b>	<b>50,851</b>	<b>57,832</b>	<b>72,529</b>	<b>76,579</b>	<b>100,938</b>
<b>Appl. of Funds</b>	<b>60,007</b>	<b>52,098</b>	<b>64,243</b>	<b>79,715</b>	<b>95,814</b>	<b>115,386</b>	<b>132,701</b>	<b>156,751</b>

## Financials and valuations

Ratios								
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Basic (INR)</b>								
EPS	36.3	45.3	52.1	68.5	55.8	61.3	76.2	97.4
Cash EPS	41.7	51.2	58.0	74.7	63.5	71.1	92.3	115.4
BV/Share	147.4	175.5	216.6	269.0	320.0	376.6	438.8	522.2
DPS	12.0	12.0	12.0	12.0	12.0	14.0	14.0	14.0
Payout (%)	39.6	26.5	23.0	17.5	21.5	19.9	18.4	14.4
<b>Valuation (x)</b>								
P/E	67.1	53.9	46.9	35.6	43.7	39.8	32.0	25.1
Cash P/E	58.5	47.7	42.1	32.7	38.4	34.3	26.4	21.1
P/BV	16.6	13.9	11.3	9.1	7.6	6.5	5.6	4.7
EV/Sales	5.6	5.0	3.7	2.4	3.1	2.9	2.3	2.0
EV/EBITDA	42.2	35.7	32.5	24.0	28.8	26.1	21.1	16.6
Dividend Yield (%)	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.6
FCF per share	51.8	121.3	60.6	1.4	29.0	69.0	-3.2	101.0
<b>Return Ratios (%)</b>								
RoE	27.7	28.1	26.6	28.2	19.0	17.6	18.7	20.3
RoCE	20.3	25.3	27.5	30.5	20.8	19.7	19.8	20.9
RoIC	21.1	27.4	34.8	40.4	28.4	28.9	27.7	30.8
<b>Working Capital Ratios</b>								
Fixed Asset Turnover (x)	4	4	5	7	5	5	4	4
Asset Turnover (x)	2.2	2.7	3.0	3.7	2.3	2.1	2.2	2.1
Inventory (Days)	75	67	70	54	76	72	65	65
Debtor (Days)	48	14	5	7	23	19	17	16
Govt Subs Receivable (days)	64	15	6	29	23	25	25	25
Creditor (Days)	135	110	100	83	119	123	110	110
Others (Days)								
Working Capital Turnover (Days)	112	56	42	45	48	56	55	46
<b>Leverage Ratio (x)</b>								
Current Ratio	2.0	1.8	1.8	1.8	1.9	2.0	2.0	2.2
Interest Cover Ratio	7	17	26	14	12	9	12	22
Debt/Equity	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Consolidated - Cash Flow Statement</b>								
							<b>(INRm)</b>	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
NP/(Loss) Before Tax and EO Items	13,777	17,806	20,460	27,253	22,150	27,276	29,967	38,226
Depreciation	1,580	1,731	1,727	1,820	2,286	2,904	4,736	5,309
Interest & Finance Charges	2,353	1,057	755	189	-448	258	-2,094	-3,720
Direct Taxes Paid	-3,135	-4,568	-4,834	-7,038	-5,478	-7,187	-7,595	-9,622
(Inc)/Dec in WC	4,044	25,476	3,716	-16,520	7,427	4,520	-7,964	4,550
<b>CF from Operations</b>	<b>18,620</b>	<b>41,502</b>	<b>21,824</b>	<b>5,703</b>	<b>25,936</b>	<b>27,771</b>	<b>17,050</b>	<b>34,743</b>
Others	0	0	-1,044	207	-11,659	-3,133	0	0
<b>CF from Operating incl EO</b>	<b>18,620</b>	<b>41,502</b>	<b>20,781</b>	<b>5,910</b>	<b>14,277</b>	<b>24,638</b>	<b>17,050</b>	<b>34,743</b>
(inc)/dec in FA	-3,434	-5,926	-3,002	-5,489	-5,732	-4,335	-18,000	-5,000
<b>Free Cash Flow</b>	<b>15,186</b>	<b>35,576</b>	<b>17,779</b>	<b>421</b>	<b>8,545</b>	<b>20,303</b>	<b>-950</b>	<b>29,743</b>
(Pur)/Sale of Investments	-105	-25	-297	-432	-5,671	-45,620	0	0
Others	1,320	-6,622	-12,921	12,312	-1,940	23,578	4,433	5,320
<b>CF from Investments</b>	<b>-2,219</b>	<b>-12,572</b>	<b>-16,220</b>	<b>6,390</b>	<b>-13,343</b>	<b>-26,377</b>	<b>-13,567</b>	<b>320</b>
Issue of Shares	1	0	0	1	0	168	0	0
Inc/(Dec) in Debt	-13,294	-16,235	-16	46	472	-516	-1,000	-500
Interest Paid	-2,353	-1,057	-755	-1,900	-1,866	-2,150	-2,340	-1,600
Dividend Paid	-4,219	-3,521	-3,522	-3,528	-3,533	-3,528	-4,122	-4,122
Others	2,654	-1,679	10,044	-10,273	18,400	14,563	64	67
<b>CF from Fin. Activity</b>	<b>-17,211</b>	<b>-22,491</b>	<b>5,751</b>	<b>-15,655</b>	<b>13,474</b>	<b>8,537</b>	<b>-7,398</b>	<b>-6,155</b>
<b>Inc/Dec of Cash</b>	<b>-810</b>	<b>6,438</b>	<b>10,312</b>	<b>-3,355</b>	<b>14,408</b>	<b>6,798</b>	<b>-3,914</b>	<b>28,908</b>
Add: Beginning Balance	1,593	783	7,221	17,533	14,178	28,586	35,384	31,469
<b>Closing Balance</b>	<b>783</b>	<b>7,221</b>	<b>17,533</b>	<b>14,178</b>	<b>28,586</b>	<b>35,384</b>	<b>31,469</b>	<b>60,378</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/ListOf200of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may: (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

\*\*\*\*\*

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com).

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: [na@motilaloswal.com](mailto:na@motilaloswal.com), Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	<a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>
Ms. Kumud Upadhyay	022 40548082	<a href="mailto:servicehead@motilaloswal.com">servicehead@motilaloswal.com</a>
Mr. Ajay Menon	022 40548083	<a href="mailto:am@motilaloswal.com">am@motilaloswal.com</a>

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dpgrievances@motilaloswal.com](mailto:dpgrievances@motilaloswal.com).